Selection of Indonesian Medicinal Plant Active Compounds as Inhibitor Candidates of Oncoproteins E6 and E7 Human Papillomavirus Type 16 by Molecular Docking

Riyanti Weni Syavitri*, Azzania Fibriani, Reza Aditama

School of Life Sciences and Technology, Bandung Institute of Technology, Indonesia.

Corresponding author; e-mail: riyanti106@students.itb.ac.id
Received 7 March, 2021
Accepted for publication 22 April, 2021

Abstract

Cervical cancer cases caused by infection with Human Papillomavirus (HPV), especially HPV 16 (60.5% of cases) continue to increase every year with a high mortality rate. The current anti-cancer drugs were not only specifically targeting cancer cells, but healthy cells and can cause serious side effects. Therefore, it is necessary to find safer alternative therapies, e.g., using active compounds from natural products. The purpose of this study was to find the active compounds of Indonesian medicinal plants potentially as an inhibitor of oncoprotein E6 and E7 HPV 16, the main protein causing cervical cancer by in silico method. In this study, 711 active compounds from 187 medicinal plant species were selected based on molecular weight, solubility, gastrointestinal absorption index, and drug-likeness. Compounds that meet the criteria were tested for their affinity and interaction profile with E6 and E7 proteins through the molecular docking method. The results of this study showed 164 compounds that met the criteria. The molecular docking analysis showed nine of the most potent compounds as E6 inhibitors on the E6AP binding site and six compounds on the p53 binding site. Besides that, there were eleven most potent compounds as E7 inhibitors. The results of this study indicate that there are natural compounds that can inhibit E6 and E7 proteins and have further potential to be used as anti-HPV drugs. However, further research is needed to test these compounds in vitro and in vivo.

Keywords: cervical cancer, E6 HPV16, E7 HPV16, inhibitor, molecular docking

1. Introduction

Cervical cancer is the second most common type of cancer in Indonesia. Based on data from WHO, there were 36,633 new cases in 2020, while the death rate from cervical cancer in the same year reached 21,003 deaths [1]. The main cause of cervical cancer is the High-Risk Human Papillomavirus (HPV) infection, identified in over 99.7% of cervical cancers [2]. HPV 16 is the most prevalent type which is detected in 60.5% of cases [3]. Although effective prophylactic HPV vaccines are readily available commercially such as Merck's Gardasil (quadrivalent vaccine) and GlaxoSmithKline's Cervarix (bivalent vaccine), the high cost of vaccination is a major barrier. Besides, this vaccine is only effective if it is given to uninfected individuals [4]. Therefore, an effective and affordable therapeutic approach is urgently needed.

The ideal anticancer drugs are those that are specific and cytotoxic only in cancer cells [5]. In cervical cancer, there are two main oncoproteins in HPV (i.e., E6 and E7), which are only expressed in infected cells that could be potential therapeutic targets. Both proteins cause cell immortalization and are continuously expressed during cancer development [6].

E6 is an 18 kD protein consist of approximately 150 amino acids [7]. The main target of E6 is tumor suppressor protein p53. E6 HPV 16 causes ubiquitination and degradation of p53 in two ways. First by binding directly to p53 (E6AP independent) or second by forming the E6 / E6AP / p53 complex (E6AP dependent). The degradation of p53 causes the uncontrolled proliferation of cells that are resistant to apoptosis [8].

E7 is the first oncoprotein discovered. This protein is relatively small, about 100 amino acids, divided into three conserved regions: CR1, CR2, and CR3 [8]. Half of the
N-terminal E7 terminals (amino acids 1-40) constituting the CR1 and CR2 regions are naturally unfolded (distinctly disordered) and are flexible with few conformational transitions [9]. Meanwhile, CR3 E7 HPV plays a role in the dimerization of E7 and becomes a medium for direct interaction with several proteins. In particular, CR3 interacts with the C-terminal portion of pRb. E7 full-length protein is 100 times more potential to bind pRb than E7 which only contains CR1 / CR2, this indicates an important role for CR3 in interactions with pRb [10]. E7 binds to pRb then causes ubiquitination of pRb so that E2F is released from pRb and becomes active. E2F is a transcription factor of genes that cells need to enter the synthesis phase in the cell cycle. The synthesis phase prompts the cell to activate DNA replication and initiates the process of self-division [8]. The combination action of E6 and E7 in cervical cells leads to cell transformation and cancer development. Hijacking E6 and E7 binding to cellular protein targets by an inhibitor could have an impact on their oncogenic activity [11].

Various types of therapies that target these two proteins have been developed, e.g., therapeutic vaccines targeting HPV 16/18 E6 / E7 for the treatment of advanced cervical cancer, genome editing using antisense oligonucleotides, ribozymes, DNAsymes, siRNA (small interfering RNA), shRNA (short-hairpin RNA), immunotherapy with synthetic E6 / E7 HPV16 / 18 DNA sequences, and tumor-infiltrating T cells (reviewed by Pal and Kundu [8]). Therapy with the E6 / E7 target gives promising results, but the high cost will be an obstacle to its application. Hence, discovering effective and more affordable alternatives becomes crucial.

The use of natural products promises a comparatively safer alternative therapeutic approach to cervical cancer. This therapy also offers less complicated treatments using abundantly available and inexpensive medicine compared to genome editing technologies or immunotherapeutic methods [8]. Natural compounds, such as plant extracts in either pure form or standardized extracts, provide unlimited opportunities for new drug discovery due to the unrivaled availability of chemical diversity [12]. The chemical diversity of natural compounds can be an excellent source of novel scaffolds. These chemical scaffolds are optimized further to get the new drug candidates.

Indonesia is a country with extraordinary high biodiversity. Indonesia’s tropical rainforests, covering an area of approximately 143 million hectares, are home to about 80% of the world’s medicinal plants [13]. Active compounds from Indonesian medicinal plants could be potential E6 and E7 inhibitors. A computational experiment or in silico method is conducted as a shortcut to seeking this great potential by creating computational models or simulations that can be used to make predictions, suggest hypotheses [14]. This method is more effective and efficient for screening new drugs for pre-eliminary research, the range of compounds being tested can be wider with a shorter time and lower cost. In this study, we explored Indonesian medicinal plants active compounds potency an oncoprotein E6 and E7 HPV 16 inhibitors by molecular docking.

2. Material and Methods

2.1. Hardware

DELL laptop with a specification of processor processor Intel® Core™ i5-7200U CPU @ 2,5 GHz RAM 8GB and 64-bit Windows 10 operating system was used in this research.

2.2. Software

Bioinformatics programs used included Marvin Sketch (ChemAxon, Budapest, Hungary), Modeller 9.16 (University of California San Francisco, USA), BIOVIA Discovery Studio Visualizer 2020 (Dassault Systèmes, San Diego), AutodockTools1.5.6 (The Scripps Research Institute, USA), Autodock Vina (TheScripps Research Institute USA) [15], LigPlot+ 2.2 (EMBL-EBI, UK) [16], and Chimera 1.14 to visualize the ligand position on the protein [17].

2.3. Protein preparation

E6 HPV 16 3D structure (chain F) was separated from E6/E6AP/p53 complex crystal structure retrieved from Protein Data Bank (PDB), ID 4XR8, and a resolution of 2,25 Å. Visualization and separation were processed by BIOVIA Discovery Studio Visualizer 2020. Polar hydrogen atoms were added to the structure and convert to *.pdbqt format by Autodock Tools 1.5.6.

E7 protein used in this research was only the CR3 domain. E7 HPV 16 sequence was harvested from the Uniprot server. The template used for modeling the 3D structure was ID2B9D (PDB id), a crystal structure of E7-CR3 domain of HPV 1A dimer with 37% identity to E7-CR3 domain of HPV 16. E7-CR3 domain of HPV 16 3D dimer structure was built by MODELLER 9.25. YASARA Energy Minimization server was used for protein model structural refinement and energy minimization [18]. The refined structure then confirmed for reliability by ProSA-Web [19] and plot to The Ramachandran plot (Zhiping weng’s laboratory, USA) [20].

2.4. Ligand preparation

There were 711 active compounds of 187 Indonesian medicinal plant species that were collected and filtered by molecular weight, solubility, GI absorption, and drug-likeness by Lipinski’s Rules of Five. The selection was carried out by submitting the 2D structure of the active compound to SwissADME webservice [21]. Compounds that have MW of more than 200 g/mol, moderate to high
solubility, high GI absorption, and fulfill drug-likeness criteria were selected and prepared for docking. The 3D conformations were drawn on Marvin Sketch by employing the dreiding force field as minimization energy.

2.5. Binding Site Identification

Identification of residues involved in E6-E6AP and E6-p53 interaction was based on E6/E6AP/p53 crystal structure complex resolved by Martinez-Zapien et al. [22] which also determined hot spot residues by mutational study and binding assay. CR3 E7 HPV 1A interaction with pRb was identified by Liu et al. [10]. Residues involved in CR3 E7 HPV 16-pRb interaction determined by amino acid sequence alignment between CR3 E7 HPV 16 and CR3 E7 HPV 1A. Pocket searching in the binding site areas of E6-E6AP, E6-p53, and CR3 E7 HPV 16-pRb were performed by fpocket webserver [23]. Those pockets were then used for the docking study.

2.6. Molecular Docking Simulation

Molecular docking was executed by Autodock Vina, a fast and accurate docking tool [15]. Grid box parameters were set in specific searching area to encompass binding site for effective docking simulation (Table 1). The docking results were visualized by LigPlot+ 2.2 in 2D and Chimera 1.14 in 3D molecular structures.

### Table 1. Grid Box Parameters

| No | Receptor | Binding Partner (Binding Site) | Grid Center Coordinate | Grid Box Size (Å) |
|----|----------|-------------------------------|------------------------|------------------|
| 1. | E6       | E6AP                          | -                      | 20 20 20         |
|    |          |                               | -7,059                 | 52,065           |
|    |          |                               | -12,871                |                  |
| 2. | E6       | p53                           | 1,947                  | 20 20 20         |
|    |          |                               | -17,234                | 61,861           |
| 3. | CR3 E7   | pRb                           | 22,31                  | 20 20 20         |
|    |          |                               | 24,86                  |                  |
|    |          |                               | 50,682                 |                  |

3. Results and discussion

The major roles of E6 and E7 oncoprotein in cervical carcinogenesis make these proteins a potential target for cervical cancer therapy [24]. Blocking both protein interactions with its cellular protein targets will be expected to have a significant impact to suppress cancer development and lead to senescence. This research aims to find Indonesian medicinal plants’ active compounds that have good potency to inhibit the interaction of oncoprotein E6 to E6AP, E6 to p53, and oncoprotein E7 to pRb. In this research, the inhibition potency of the active compounds was evaluated by molecular docking to E6 and E7.

3.1. Active compounds selection

Active compounds were filtered by molecular weight, solubility, GI absorption, and drug-likeness (Lipinski’s rules of five). Low molecular weight compounds bound weakly to protein [25], so only compounds that have a molecular weight above 200 g/mol used in this study. Compound solubility in water is important for drug formulation to achieve the desired concentration of drug in systemic circulation for desired pharmacological response [26]. The GI absorption parameter was observed in this study because this parameter is related to the absorption rate of the compound in the intestine and its bioavailability. High GI absorption is very important for oral drug candidates. The oral route is the most common and preferred way of administration over other routes because of its many advantages. These advantages include safety, ease of administration, high patient compliance, painlessness, cost-effectiveness, and flexibility in dosage form design [27]. The Lipinski’s rule of five helps to distinguish a drug-like compound from a non-drug based on five rules: molecular mass < 500 Da, lipophilicity (LogP < 5), hydrogen bond donors < 5, hydrogen bond acceptors < 10, molar refractivity should be within 40 to 130.28 [28]. Active compounds selection results in 164 compounds that meet the criteria.

3.2. Binding Affinity and Molecular Interaction Profile

E6 oncoprotein was docked in two binding sites: E6-E6AP interface and E6-p53 interface. Residues involved in E6-E6AP interaction are R10, K11, V31, Y32, L50, C51, V53, R55, V62, L67, Y70, S74, R77, H78, L100, R102, Q107, R129, and R131. L50, R102, and R131 are considered hot spot residues because of their high contribution for E6AP binding. Mutation of these residues leads to binding perturbation, prevents p53 degradation, and disrupts the oncogenic activity of E6 [29].

Docking results of active compounds to E6 in E6AP interface are shown in Table 2. Table 2 shows active compounds with the best docking score to E6 at E6AP binding site and a standard anticancer drug (i.e., jaceosidin) as a positive control. Jaceosidin is a flavonoid from
Artemisia princeps which experimentally through the ELISA method has the potential as an inhibitor of oncoproteins E6 and E7. In vitro testing on SiHa and CaSki cell lines containing the HPV 16 genome shows jaceosidin inhibits cancer formation [30]. Nine compounds, i.e., elephantin, roemerine, ginkgolide A, phaseollin, anonaine, chitranone, elephantopin, tetrahydroalstonine and vindolinine have significantly lower docking score (-8.3 to -8.7 kcal/mol) than positive control (-7.2 kcal/mol). The lower docking score or binding affinity indicate the more stable and favorable the interaction. The nine compounds have better affinity to E6 than jaceosidin because they have more hydrophobic interactions. Figure 2.a shows that the elephantin interact with nine hydrophobic residues of E6 (Y32, L50, V3, V62, L67, Y70, S71, S74, R102) or 47.37% compared to total 19 residues involved in E6-E6AP protein-protein interaction. While jaceosidin has only three hydrophobic interactions (L50, Q107, R131) or 31.58% (Figure 1.a). Elephantin atomic groups are mostly in the hydrophobic E6 protein residue (dark orange color), shown in Figure 2.b. Hydrophobic interaction can increase the affinity in the protein-ligand complex. The addition of the number of hydrophobic atoms at the active site of the target and drug interface affects the biological activity of the drug candidate. The increase in binding affinity to the target complex and the drug that results from the optimization of hydrophobic interactions shows better drug efficacy [31]

### Table 2. Docking Results of Indonesian Medicinal Plant Active Compounds against Oncoprotein E6 on the Binding Site of E6AP

| Active Compound | Plant Spesies | Docking Score/Binding Affinity (kcal/mol) | Hydrogen Bonds | Hydrophobic Interaction | Total Interaction |
|-----------------|---------------|------------------------------------------|----------------|------------------------|-------------------|
| Jaceosidin      | Artemisia princeps (Mugwort Korea) | -7.2 | L100, W132, R102, C51 | **L50**, Q107, R131 | 31.58% |
| Elephantin      | Elephantopus scaber (tapak liman) | -8.7 | C51, Q107, R131 | **L50**, L50, V53, V62, L67, Y70, S71, S74, R102 | 47.37% |
| Roemerine       | Nelumbo nucifera (teratai) | -8.7 | - | **L50**, C51, V53, V62, Y70, S71, Q107, R131 | 47.37% |
| Ginkgolide A    | Ginkgo biloba (ginkgo biloba) | -8.6 | - | **L50**, C51, V53, A61, V62, L67, Q107, R102, L50, C51, V53, Y32, L50, | 42.10% |
| Phaseollin      | Erythrina fusca (cangkring) | -8.6 | - | **L50**, C51, V53, A61, V62, L67, Q107, R102, L50, C51, V53, Y32, L50, | 52.63% |
| Anonaine        | Annona squamosa (srikaya) | -8.5 | - | **L50**, V62, L67, L100, Q107, R102, L50, V62, L67, Q107, R131 | 47.37% |
| Chitranone      | Plumbago zeylanica (daun encok) | -8.4 | C51, R102 | **L50**, V62, L67, L100, Q107, R131 | 42.10% |
| Elephantopin    | Elephantopus scaber (tapak liman) | -8.4 | C51, R131 | **L50**, L50, V53, V62, L67, Y70, S71, S74, Q107 | 52.63% |
| Tetrahydroalstonine | Catharanthus roseus (tapak dara) | -8.3 | **R102**, Y32, F45, L50, C51, V53, A61, V62, L67, S71, S74, Q107, R131 | 57.89% |
| Vindolinine     | Catharanthus roseus (tapak dara) | -8.3 | Q107 | **L50**, C51, V62, L67, Y70, S71 | 31.57% |
Having three hydrogen bonds, elephantin has better specificity among the nine compounds. Hydrogen bonding is a fundamental interaction in protein-ligand complexes and is the main reason for the selectivity of ligand proteins, due to its specific nature, short spacing, and directionality [32-33]. Docking programs generally model hydrogen bond interactions better than hydrophobic interactions. This relates to the need for specificity in drug design [33].

The compound's interaction with hot spot protein residues also affects its potential as inhibitor. Hot spot residues are crucial residues for protein-protein interactions, so that intervention in these residues has an impact on their binding. L50, R102, and R131 are hot spot residues in E6-E6AP interaction. Elephantin, phaseolin, chitranone, and tetrahydroalstonine have interactions with all these residues via hydrogen bonding and/or hydrophobic interaction so that these compounds could have better potency as E6 inhibitors.

Molecular docking was also executed on p53 binding site, to simulate inhibition of E6-p53 direct interaction by active compounds. Molecular interaction profile of best docking
score compounds shown in Table 3. D44, F47, and D49 were known to be E6 hot spot residues in E6-p53 interaction base on research conduct by Martinez-Zapien et al. [22]. E6 also interacts with p53 via I23, H24, and Y43. All these six residues lay on the center of E6-p53 interaction. Table 2 exhibits six compounds that are chitranone, sesamin, 16-acetylgitoxigenin, tetrahydroalstonine, methylphioigoneone A, and phaseollin have a significantly better binding affinity (-6.9 kcal/mol to -7.3 kcal/mol) to E6 on p53 binding site than the positive control. Chitranone, sesamin, and 16-Acetylgitoxigenin have lower docking scores despite their fewer interactions that control positive, probably because of the better fitness compound to E6 surface interaction or shorter inter-atomic surface distance between compounds and protein. Surface distance is one of the parameters calculated in Autodock Vina scoring function. Binding affinity and hydrophobic interaction of the six best compounds do not differ significantly, but tetrahydroalstonine, methylphioigoneone A, and phaseollin show better specificity by having more hydrogen bonds.

E7 key role in cancer initiation work in concert with E6. Blocking both protein interaction with cellular protein is important to completely suppress their oncogenic activities. The CR3 E7 residues that interact with pRb are R66, L67, I76, R77, E80, D81, M84. Based on the mutational study conducted by Liu et al. [10], a single mutation in the R66 residue and a mutation in the E80 / D81 residue had a significant effect in inhibiting the interaction of E7 with pRb. Therefore R66, E80, D81 are defined as hot spot residues. Molecular docking performed to CR3 E7 HPV16 results 11 best compounds shown in Table 4.

Table 3. Docking Results of Indonesian Medicinal Plant Active Compounds against Oncoprotein E6 on the Binding Site of p53

| Active Compound         | Plant Spesies  | Docking Score/Binding Affinity (kcal/mol) | Hydrogen Bonds | Hydrophobic Interaction | Total Interaction |
|-------------------------|----------------|------------------------------------------|----------------|-------------------------|-------------------|
| Jaceosidin (positive control) | Artemisia princeps (Mugwort Korea) | -6.1 | D44, R48, C106, S111 | L108, E114, M137, S138 | 16.67% |
| Chitranone              | Plumbago zeylanica (daun encok) | -7.3 | K108 | Y43, F47, S111, E114, M137 | 33.33% |
| Sesamin                 | Piper retrofractum (cabe jawa)  | -7.1 | R48 | Y43, D44, F47, S138 | 50% |
| 16-Acetylgitoxigenin    | Nerium indicum (jure)           | -7.0 | R48 | R40, Y43, D44, F47, C106, K108 | 50% |
| Tetrahydroalstonine     | Catharanthus roseus (tapak dara) | -7.0 | S138, R48, D44 | R40, Y43, F47, C106, K108 | 50% |
| Methylphioigoneone A    | Ophiopogon japonicus (ophiopogon) | -6.9 | R48, K108, S138 | D44, F47, C106, S111, E144, M137 | 33.33% |
| Phaseollin              | Erythrina fusca (cangkring)     | -6.9 | E114, M137, S138 | Y43, D44, F47, K108, C136 | 50% |
### Table 4. Docking Results of Indonesian Medicinal Plant Active Compounds against Oncoprotein E7 on the Binding Site of pRb

| Active Compound | Plant Species                  | Docking Score/Binding Affinity (kcal/mol) | Hydrogen Bonds | Hydrophobic Interaction | Total Interaction |
|-----------------|--------------------------------|------------------------------------------|----------------|-------------------------|-------------------|
| Jaceosidin (positive control) | *Artemisia princeps* (Mugwort Korea) | -5.8 | Q70, D81 | R66, V74, T78, L82, L87, T86, G88 | 28.57% |
| Columbin        | *Tinospora crispa* (brotovali)   | -6.9 | R66 | N53, V55, Q70, T78, D81, L82, T86, G88 | 28.57% |
| Methylophiogonone A | *Ophiopogon japonicus* (ophiopogon) | -6.9 | D81 | N53, V55, R66, T64, Q70, V74, R77, T78, L82, T86, G88 | 42.86% |
| Serpentine      | *Rauvolfia serpentina* (pule pandak) | -6.8 | - | R66, V74, T78, D81, L82, T86, L87, G88 | 42.86% |
| Uzarigenin      | *Nerium indicum* (jure)          | -6.8 | N53 | D81, L82, T86, L87, G88 | 28.57% |
| Apigenin        | *Apium graveolens* (seledri)     | -6.6 | N53, D81 | R66, T78, L82, T86, G88 | 28.57% |
| Coumestrol      | *Taraxacum officinale* (jombang) | -6.6 | N53 | V55, T64, R66, T78, L82, T86, G88 | 14.29% |
| Kaempherol      | *Garcinia latissima* (dolo magota) | -6.6 | N53, T64, D81 | V55, L65, R66, T78, L82, G88 | 28.57% |
| Phaseollin      | *Erythrina fusca* (cangkring)    | -6.6 | N53 | V55, R66, T78, D81, L82, L87, G88 | 28.57% |
| Pelargonidin    | *Phaseolus vulgaris* (buncis), *Impatiens balsamina* (pacar air) | -6.5 | N53, T64, D81 | V55, L65, R66, T78, L82, G88 | 28.57% |
| Rhamnocrin     | *Alpinia galanga* (lengkuas)     | -6.5 | N53 | V55, T64, R66, T78, D81, L82, T86, G88 | 28.57% |
| Sesamin         | *Piper retrofractum* (cabe jawa) | -6.5 | - | R66, V74, T78, D81, L82, T86, G88 | 42.86% |

Table 4 shows the 11 compounds with the best docking scores (-6.5 to -6.9 kcal/mol). This score was significantly better than the positive control docking score. Kaempherol and pelargonidin have relatively better specificity compared to positive control and other compounds because of their hydrogen bonds. All compounds have interactions with hot spot residues either through hydrogen bonds or hydrophobic interactions, so that they have good potency as E7 inhibitors. The total interactions that occurred between the compounds ranged from 28.57% to 42.86%, except for coumestrol which was slightly smaller, namely 14.29%. Based on the results in Table 4, it is concluded that the compounds columbin, methylophiogonone A, serpentine, uzarigenin, apigenin, coumestrol, kaempherol, phaseollin, pelargonidin, rhamnocrin, and sesamin are potential inhibitors of E7.

Among the compounds that have the potential to act as inhibitors of E6-E6AP, E6-p53, and E7-pRb, phaseollin can be potential inhibitors of the three interactions. Meanwhile, compounds that have the potential to act as inhibitors of E6-E6AP and E6-p53 are chitranone and tetrahydroalstonine.
Sesamin and methylophiogonone A have the potential to inhibit E6-p53 and E7-pRb interactions. Further research is needed to determine the potential of the best compounds obtained in this study in vitro and in vivo.

4. Conclusion

The diversity of Indonesian medicinal plants provides as abundant active compounds source for anti-cancer drug discovery. Cervical cancer caused by HPV 16 infections, develop as impact of continuous expression of E6 and E7 oncoproteins in infected cells. In this study, we explored Indonesian medicinal plants active compounds potency an oncoprotein E6 and E7 HPV 16 inhibitors by molecular docking. By observing the docking score, hydrogen bonding, hydrophobic interactions, and interactions of compounds with E6/E7 hot spot protein residues, we suggest potential E6/E7 inhibitors. Elephantin, roemerine, ginkgolide A, phaseollin, anonaine, chitranone, elephantopin, tetrahydroalstonine and vindolinine were found to be potential as E6 inhibitors on E6AP binding site. Columbin, methylophiogonone A, and phaseollin exhibit potency as E6 inhibitors on p53 binding site. Columbin, methylophiogonone A, serpentine, uzarigenin, apigenin, coumestrol, phaseollin, pelargonidin, rhamnocitrin, and sesamin showed potency as E7 inhibitors. Phaseollin was found to be potential as E6 and E7 inhibitors.

References

[1] World Health Organization (WHO). Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. WHO; 2020. Accessed December 11, 2020. https://geo.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf

[2] Smola S. Immunopathogenesis of HPV-associated cancers and prospects for immunotherapy. Viruses. 2017 Sep;9(9):254. DOI: https://doi.org/10.3390/v9090254

[3] Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best practice & research Clinical obstetrics & gynaecology. 2018 Feb 1;47:14-26. DOI: https://doi.org/10.1016/j.bpobgyn.2017.08.006

[4] Murillo R, Ordoñez-Reyes C. Human papillomavirus (HPV) vaccination: From clinical studies to immunization programs. International Journal of Gynecologic Cancer. 2019 Oct 1;29(8). DOI: http://dx.doi.org/10.1136/ijgc-2019-000582

[5] Singh S, Sharma B, Kanwar SS, Kumar A. Lead phytochemicals for anticancer drug development.

[6] Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Frontiers in microbiology. 2020 Jan 21;10:3116. DOI: https://doi.org/10.3389/fmicb.2019.01336

[7] García-Alai MM, Alonso LG, de Prat-Gay G. The N-terminal module of HPV16 E7 is an intrinsically disordered domain that confers conformational and recognition plasticity to the oncoprotein. Biochemistry. 2007 Sep 18;46(37):10405-12. DOI: https://doi.org/10.1021/bi7010791

[8] Liu X, Clements A, Zhao K, Marmarstein R. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. Journal of Biological Chemistry. 2006 Jan 6;281(1):578-86. DOI: https://doi.org/10.1074/jbc.M50485200

[9] Hoppe-Seyler K, Bossier F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 oncoproteins: key factors for viral carcinogenesis and therapeutic targets. Trends in microbiology. 2018 Feb 1;26(2):158-68. DOI: https://doi.org/10.1016/j.tim.2017.07.007

[10] Cos P, Vlietinck AJ, Berghé DV, Maes L. Anti-infec-tive potential of natural products: How to develop a stronger in vitro ‘proof-of-concept’. Journal of ethnopharmacology. 2006 Jul 19;106(3):290-302. DOI: https://doi.org/10.1016/j.jep.2006.04.003

[11] Woerdenbag HJ, Kayser O. Jamu: Indonesian traditional herbal medicine towards rational phytopharmacological use. Journal of herbal medicine. 2014 Jun 1;4(2):51-73. DOI: https://doi.org/10.1016/j.jhermed.2014.01.002

[12] Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British journal of pharmacology. 2007 Sep;152(1):9-20. DOI: 10.1038/sj.bjp.0707305

[13] Trot O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function. Frontiers in plant science. 2016 Nov 8;7:1667. DOI: https://doi.org/10.3389/fpls.2016.01667

[14] Sher YP, Lee C, Liu SY, Chen IH, Lee MH, Chiu FF, Leng CH, Liu SJ. A therapeutic vaccine targeting HPV E6/E7 with intrinsic Toll-like receptor 2 agonist activity induces antitumor immunity. American journal of cancer research. 2018;8(12):2528. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30662809

[15] Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer research and treatment: official journal of Korean Cancer Association. 2005 Dec;37(6):319. DOI: https://dx.doi.org/10.4143%2Fjert.2005.37.6.319
function, efficient optimization, and multithreading. Journal of computational chemistry. 2010 Jan 30;31(2):455-61. DOI: https://doi.org/10.1002/jcc.21334

[16] Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein engineering, design and selection. 1995 Feb 1;8(2):127-34. DOI: https://doi.org/10.1093/protein.8.2.127

[17] Pettiens EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera—a visualization system for exploratory research and analysis. Journal of computational chemistry. 2004 Oct;25(13):1605-12. DOI: https://doi.org/10.1002/jcc.20084

[18] Krieger E, Joo K, Lee J, Lee J, Raman S, Thompson J, Tyka M, Baker D, Karplus K. Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins: Structure, Function, and Bioinformatics. 2009;77(S9):114-22. DOI: https://doi.org/10.1002/prot.22570

[19] Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic acids research. 2007 Jul 1;35(suppl 2):W407-10. DOI: https://doi.org/10.1093/nar/gkm290

[20] Anderson RJ, Weng Z, Campbell RK, Jiang X. Main-chain conformational tendencies of amino acids. Proteins: Structure, Function, and Bioinformatics. 2005 Sep 1;60(4):679-89. DOI: https://doi.org/10.1002/prot.20530

[21] Daina A, Michielet O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports. 2017 Mar 3;7(1):1-3. DOI: 10.1038/srep42717

[22] Martínez-Zapien D, Ruiz FX, Poisson J, Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Pol SV, Podjarny A, Trave G. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016 Jan;529(7587):541-5. DOI: 10.1038/nature16481

[23] Le Guilloux V, Schmidtke P, Tuffery P. FPocket: an open source platform for ligand pocket detection. BMC bioinformatics. 2009 Dec;10(1):1-1. DOI: https://doi.org/10.1186/1471-2105-10-168

[24] Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nature Reviews Cancer. 2017 Feb;17(2):93-115. DOI: 10.1038/nrc.2016.138

[25] Houston DR, Yen LH, Pettit S, Walkinshaw MD. Structure-and ligand-based virtual screening identifies new scaffolds for inhibitors of the oncoprotein MDM2. PLoS One. 2015 Apr 17;10(4):e0121424. DOI: https://doi.org/10.1371/journal.pone.0121424

[26] Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. International Scholarly Research Notices. 2012;2012: DOI: https://doi.org/10.5402/2012/195727

[27] Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery—a review. Pharmaceutical science & technology today. 2000 Apr 1;3(4):138-45. DOI: 10.1016/S1461-5347(00)00247-9

[28] Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug discovery today: Technologies. 2004 Dec 1;1(4):337-41. DOI: https://doi.org/10.1016/j.ddtect.2004.11.007

[29] Zanier K, Charbonnier S, Sidi AO, McEwen AG, Ferrario MG, Poussin-Courmontagne P, Cura V, Brimer N, Babah KO, Ansari T, Muller I. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science. 2013 Feb 8;339(6120):694-8. DOI: https://doi.org/10.1126/science.1229934

[30] Lee HG, Yu KA, Oh WK, Baeg TW, Oh HC, Ahn JS, Jang WC, Kim JW, Lim JS, Choe YK, Yoon DY. Inhibitory effect of jaceosidin isolated from Artemisia argyi on the function of E6 and E7 oncoproteins of HPV 16. Journal of ethnopharmacology. 2005 Apr 26;98(3):339-43. DOI: https://doi.org/10.1016/j.jep.2005.01.054

[31] Patil R, Das S, Stanley A, Yadav L, Sudhakar A, Varma AK. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PloS one. 2010 Aug 16;5(8):e10209. DOI: https://doi.org/10.1371/journal.pone.0012029

[32] Nittinger E, Inhester T, Bietz S, Meyder A, Schomburg KT, Lange G, Klein R, Rarey M. Large-scale analysis of hydrogen bond interaction patterns in protein–ligand interfaces. Journal of medicinal chemistry. 2017 May 25;60(10):4245-57. DOI: https://doi.org/10.1021/acs.jmedchem.7b00101

[33] Motiejuan D, Wade RJ. Computer-Assisted Drug Design. In Triggle DJ, Taylor JB, editors. Comprehensive Medicinal Chemistry II. Elsevier; 2006 Dec 29.